Royalty Pharma plc
RPRX
$45.53
$0.731.63%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 2.08% | 5.29% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 2.08% | 5.29% | |||
| Cost of Revenue | 90.40% | 105.95% | |||
| Gross Profit | 0.29% | -23.70% | |||
| SG&A Expenses | 60.00% | -53.95% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 45.31% | -48.81% | |||
| Operating Income | -16.20% | 90.46% | |||
| Income Before Tax | -19.88% | 390.11% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -19.88% | 390.11% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 9.16% | -158.02% | |||
| Net Income | -25.68% | 855.12% | |||
| EBIT | -16.20% | 90.46% | |||
| EBITDA | -16.17% | 90.45% | |||
| EPS Basic | -42.26% | 835.90% | |||
| Normalized Basic EPS | -75.14% | 82.17% | |||
| EPS Diluted | -42.09% | 838.50% | |||
| Normalized Diluted EPS | -67.80% | 86.81% | |||
| Average Basic Shares Outstanding | 28.74% | 1.98% | |||
| Average Diluted Shares Outstanding | -0.65% | -0.48% | |||
| Dividend Per Share | 0.00% | 0.00% | |||
| Payout Ratio | 0.33% | -0.89% | |||